8-K
filed September 15, 2023, 7:59 PM ET
ticker EVFM
CIK 0001618835
other material
confidence high
sentiment negative
materiality 0.80
Evofem shareholders approve increase in authorized common shares to 3 billion
Evofem Biosciences, Inc.
- Authorized common shares increased to 3,000,000,000 (from previous amount) effective Sept 15, 2023.
- Saundra Pelletier re-elected as Class III director; advisory say-on-pay approved with 4.75M votes for.
- BPM LLP ratified as independent auditor for FY 2023; all proposals passed with large majorities.
- Meeting quorum: 5,011,486 votes (58.6% of eligible) with common stock holders representing 13%.
- Massive authorized share increase signals potential substantial dilution for existing shareholders.
Key facts
Extracted from this filing and checked against the source text.
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
Evofem Biosciences, Inc.: Increased total authorized common shares to 3,000,000,000 (effective 2023-09-15).
- Change
- charter amendment
- Effective
- 2023-09-15
Exact text from the filing
the Company’s stockholders approved a resolution to amend the Company’s existing Amended and Restated Certificate of Incorporation (“Certificate”)
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 1.0
Evofem Biosciences, Inc. shareholders approved Ratification of the appointment of BPM LLP as the Company's Independent Registered Public Accounting firm for the year ending December 31, 2023 at the 2023-09-14 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2023-09-14
Exact text from the filing
Proposal 4 Ratification of the appointment of BPM LLP as the Company’s Independent Registered Public Accounting firm for the year ending December 31, 2023. Votes For Votes Against Votes Withheld Broker Non-Vote 4,943,298 34,100 34,088 -
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 1.0
Evofem Biosciences, Inc. shareholders approved Approval, on a non-binding advisory basis, of the compensation of our named executive officers at the 2023-09-14 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2023-09-14
Exact text from the filing
Proposal 2 Approval, on a non-binding advisory basis, of the compensation of our named executive officers. Votes For Votes Against Votes Withheld Broker Non-Vote 4,754,413 185,842 71,231 -
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 1.0
Evofem Biosciences, Inc. shareholders approved Election of Saundra Pelletier as a Class III director at the 2023-09-14 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2023-09-14
Exact text from the filing
Proposal 1 Election of the following nominee as a Class III director of the company, to serve a three-year term until the 2026 Annual Meeting of Stockholders and until her successor is duly elected and qualified. Votes For Votes Against Votes Withheld Broker Non-Vote Saundra Pelletier 4,821,109 - 190,377 -
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 1.0
Evofem Biosciences, Inc. shareholders approved Approval of the amendment to the Company's Restated Certificate to authorize an increase in the total number of common shares authorized to 3,000,000,000 at the 2023-09-14 meeting.
- Proposal
- charter amendment
- Outcome
- passed
- Meeting
- 2023-09-14
Exact text from the filing
Proposal 3 Approval of the amendment unanimously approved by the Company’s board of directors to the Company’s Restated Certificate to authorize an increase in the total number of common shares authorized to 3,000,000,000. Votes For Votes Against Votes Withheld Broker Non-Vote 4,722,280 271,079 18,127 -
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.